Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
11.73
Nov 06 • 3:59 PM ET Dollar change-0.08 Percentage change(-0.68%)
Aftermarket Close
11.73
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
493.30M
Enterprise Value
470.07M
Income
-32.94M
Sales
325.38M
Book/sh
3.86
Cash/sh
0.81
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
632
IPO
May 27, 2004
P/E
-
Forward P/E
-
PEG
-
P/S
1.52
P/B
3.04
P/C
14.52
P/FCF
-
EV/EBITDA
163.22
EV/Sales
1.44
Quick Ratio
1.48
Current Ratio
2.40
Debt/Eq
0.07
LT Debt/Eq
0.05
Option/Short
Yes / Yes
EPS (ttm)
-0.79
EPS next Y
-0.10
EPS next Q
-0.07
EPS this Y
-82.03%
EPS next Y
61.55%
EPS next 5Y
-
EPS past 3/5Y
12.67% -1.46%
Sales past 3/5Y
-1.86% 1.93%
EPS Y/Y TTM
-0.88%
Sales Y/Y TTM
8.20%
EPS Q/Q
36.22%
Sales Q/Q
6.87%
Insider Own
11.52%
Insider Trans
-1.00%
Inst Own
89.69%
Inst Trans
-1.85%
ROA
-12.98%
ROE
-19.21%
ROIC
-19.05%
Gross Margin
52.34%
Oper. Margin
-6.01%
Profit Margin
-10.12%
SMA20
-0.52%
SMA50
-14.94%
SMA200
-6.21%
Trades
Shs Outstand
42.42M
Shs Float
37.21M
52W High
16.29 -27.99%
52W Low
9.39 24.92%
Volatility
5.39% 5.03%
ATR (14)
0.61
RSI (14)
39.46
Beta
0.28
Rel Volume
0.56
Avg Volume
650.15K
Volume
363,728
Perf Week
-2.17%
Perf Month
4.45%
Perf Quarter
-25.52%
Perf Half Y
4.73%
Perf YTD
-8.64%
Perf Year
0.00%
Perf 3Y
74.55%
Perf 5Y
-62.12%
Perf 10Y
-25.99%
Prev Close
11.81
Price
11.73
Change %
-0.68%
Consensus
Strong Buy
Avg. Price Target
$18.33
Implied Upside
+56.3%
Analysts11incl. previous ratings
Rating Distribution6 Buy · 5 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 16, 2025Initiated
LLake Street
Buy$24+104.6%
Apr 05, 2024Upgrade
OPY logoOOppenheimer
Perform → Outperform$12+2.3%
Sep 25, 2023Initiated
HH.C. Wainwright
Buy$19+62.0%
Apr 17, 2023Downgrade
RJF logoRRaymond James
Strong Buy → Outperform$14 → $13+10.8%
Oct 15, 2021Upgrade
CCanaccord Genuity
Hold → Buy$28 → $37+215.4%
Aug 20, 2021Initiated
OPY logoOOppenheimer
Perform
Nov 25, 2020Upgrade
RJF logoRRaymond James
Mkt Perform → Strong Buy$18+53.5%
Apr 08, 2020Downgrade
KEY logoKKeyBanc Capital Markets
Overweight → Sector Weight
Apr 01, 2019Upgrade
KEY logoKKeyBanc Capital Markets
Sector Weight → Overweight
Apr 03, 2018Upgrade
RJF logoRRaymond James
Mkt Perform → Outperform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trowbridge Stephen AEVP and CFOOct 29 '26Sale12.2723,615289,756280,461Oct 30 04:15 PM
Trowbridge Stephen AEVP and CFOOct 28 '26Sale12.171,72020,932304,076Oct 30 04:15 PM
STEPHEN TROWBRIDGEOfficerOct 29 '26Proposed Sale12.2723,615289,722Oct 29 04:02 PM
Nighan Warren JRSVP Quality and RegulatoryJul 30 '26Sale14.7223,370344,00664,745Jul 31 04:45 PM
WARREN NIGHANOfficerJul 30 '26Proposed Sale14.7223,370344,004Jul 30 06:02 PM
Piccinini LauraSVP InternationalJul 22 '26Option Exercise0.008,047086,435Jul 24 06:10 PM
Nighan Warren JRSVP Quality and RegulatoryJul 22 '26Option Exercise0.005,694089,786Jul 24 06:10 PM
Trowbridge Stephen AEVP and CFOJul 22 '26Option Exercise0.0016,2960314,115Jul 24 06:10 PM
Clemmer James CPresident and CEOJul 22 '26Option Exercise0.0052,3580889,176Jul 24 06:10 PM
Campbell Chad ThomasSVP/GM, Vascular AccessJul 22 '26Option Exercise0.006,4660111,006Jul 24 06:10 PM
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The firm offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The Med Tech segment consists of technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment focuses on core, venous, ports, and other oncology products. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.
CEOMr. James C. Clemmer
Executive VP & CFOMr. Stephen A. Trowbridge
Senior VPMr. Lawrence T. Weiss
Senior Vice President of Regulatory AffairsMr. Warren G. Nighan
Senior VP and GM of Cardiovascular & InternationalMs. Laura Piccinini